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Abstract
Since the discovery of RNAi and microRNAs more than 10 years ago, much research has focused on the development of
systems that usurp microRNA pathways to downregulate gene expression in mammalian cells. One of these systems makes
use of endogenous microRNA pri-cursors that are expressed from polymerase II promoters where the mature microRNA
sequence is replaced by gene specific duplexes that guide RNAi (shRNA-miRs). Although shRNA-miRs are effective in
directing target mRNA knockdown and hence reducing protein expression in many cell types, variability of RNAi efficacy in
cell lines has been an issue. Here we show that the choice of the polymerase II promoter used to drive shRNA expression is
of critical importance to allow effective mRNA target knockdown. We tested the abundance of shRNA-miRs expressed from
five different polymerase II promoters in 6 human cell lines and measured their ability to drive target knockdown. We
observed a clear positive correlation between promoter strength, siRNA expression levels, and protein target knockdown.
Differences in RNAi from the shRNA-miRs expressed from the various promoters were particularly pronounced in immune
cells. Our findings have direct implications for the design of shRNA-directed RNAi experiments and the preferred RNAi
system to use for each cell type.
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Introduction
RNA interference (RNAi) is a process of double-stranded RNA-
dependent post-transcriptional gene silencing. It has become the
mostpowerful andwidely used strategyforgeneticanalysis based on
the highly specific and efficient silencing of target genes [1,2,3].
Upon cell entry, double-stranded RNA is cleaved by the RNAse III
enzyme Dicer into double-stranded small interfering RNAs
(siRNAs) of ,21–23 nt in length with a two-base 39 overhang
[4,5]. These short-interfering RNAs (siRNAs) are subsequently
incorporated into the RNA-induced silencing complex (RISC),
which uses one strand of the siRNA as a guide to target the
complementary mRNA for degradation by RNA cleavage directed
by Ago2 [6]. In this manner, RNAi allows for the sequence-specific
degradation of mRNAs expressed in the cell, thereby lowering the
expression level of the encoded proteins (protein knockdown).
The discovery of RNAi has led to the development of methods
that usurp the RNAi pathway to specifically degrade specific
mRNA molecules thereby allowing loss-of-function phenotype
studies in mammalian cells. Of these, commercial synthetic
siRNAs are most widely used as means to target complementary
cellular mRNAs[7]. More recently much attention has been given
to the development of genetically encoded siRNAs by expressing
so-called short hairpin RNAs (shRNAs) in a cell, consisting of a
sequence of ,21–25 nt, a short loop region, and the reverse
complement of the 21- to 25-nt region driven by a polymerase
(pol) III promoter such as U6 or H1 [3,8,9,10,11]. When
transcribed in vivo, this short transcript forms a hairpin structure,
which is subsequently converted by Dicer into short RNAs that are
recognized by the RNA-induced silencing complex and induce
mRNAs cleavage.
The shRNA stem-loop is structurally related to microRNA
(miRNA) precursor stem-loop RNAs. miRNA precursors encode a
highly conserved class of endogenous 21 to 23-nucleotide-long
microRNAs. These small RNAs were originally described in
worms and display less complete sequence complementarity to
their targets as compared to shRNAs [12,13], but also act by
inducing gene silencing [12,13,14,15,16]. miRNAs are transcribed
as part of long primary transcripts (pri-miRNAs); the pri-miRNAs
are cleaved by the nuclear Drosha-DGCR8 microprocessor
complex to produce approximately 70 nt stem-loop structures of
precursor miRNAs (pre-miRNAs). The pre-miRNAs are subse-
quently transported from the nucleus to the cytoplasm by
Exportin-5, where they are subjected to cleavage by the RNase
III enzyme Dicer to yield a 20–23 nt double-stranded RNA
siRNA of which the mature miRNA strand is loaded into RISC,
and guides mRNAs target cleavage or more often inhibition of
protein synthesis (reviewed in Ku and McManus [1]).
Whereas polymerase III expressed shRNAs are modeled after
precursor miRNAs, other systems are modeled after primary
miRNA transcripts in which the shRNA is flanked by genomic
miRNA sequences that are naturally present in miRNA genes
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(shRNA-miRs) are expressed from polymerase II promoters and
feed into the miRNA biosynthesis pathway upstream the micro-
processor cleavage step. Since these shRNA-miRs usurp the entire
miRNA processing machinery, they are considered to be a more
‘natural’ system to induce RNAi; additionally several reports have
suggested that these shRNAs are more potent in driving target
knockdown as polymerase III expressed shRNAs [19,20,21,24,25].
These systems have been mass-produced in lentiviral vectors since
lentivirusoffersshRNAintroductioninto a wide varietyofcelltypes.
In addition, many– if not most lentiviral shRNA constructs use the
CMV pol II promoter to drive shRNA expression, given the
promoter’s activity in a wide variety of cell types.
We observed that shRNA-miRs expressed from commonly used
polymerase II promoters are often less effective in driving target-
gene knockdown as compared to ‘conventional’ shRNAs expressed
from the polymerase III U6 promoter. Our studies indicate that
the potency of knockdown using shRNA-miRs is largely
determined by the relative promoter strength of the polymerase
II promoter that drives expression of the shRNA, and that large
variations in target knockdown occur due to the differential
potency of such promoters in different cell types. These data
support a model where small RNA abundance is a limiting factor
for the activity of shRNAs and perhaps microRNAs. To our
knowledge this has not been formally tested in the context of
shRNAs. Importantly, our findings have direct implications for the
design of shRNA-directed RNAi experiments and the choice
which RNAi system to use for which cell type.
Results
anti-EGFP shRNAs expressed from a miRNA backbone are
less efficient in target-knockdown in Jurkat T cells as
compared to 293T cells
In the process of generating stable EGFP knockdown cell lines
in human Jurkat T cells by using an anti-EGFP shRNA expressed
Figure 1. anti-EGFP shRNAs expressed from a miRNA backbone are less efficient in target-knockdown in Jurkat T cells than in 293T
cells. A) schematic representation of the miR-context anti-EGFP shRNA construct cloned in the 39UTR of mCherry which is expressed under the
control of the polymerase II CMV promoter (lower panel) and the control anti-EGFP shRNA expressed from a mouse polymerase III U6 promoter (top
panel). B) EGFP-expressing Jurkat T cells (top panels) or 293T cells (lower panels) were infected at an MOI of ,0.2 with anti-EGFP shRNAs expressed
from a mouse U6 promoter (U6 anti-EGFP shRNA) or from a miR-30 backbone expressed from a CMV promoter (miR-context anti-EGFP shRNA) or the
relevant control viruses that lack shRNA inserts. Cells were allowed to grow for 8 days and the expression of EGFP (to monitor knockdown) and
mCherry (as marker for infected cells) were assessed by flow cytometry. The indicated percentage of EGFP knockdown is calculated by ((Geo-mean of
uninfected cells minus Geo-mean of infected cells)/Geo-mean of uninfected cells)*100. The presented data is a representative experiment of 2
experiments performed in triplicate.
doi:10.1371/journal.pone.0026213.g001
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miRs, see Figure 1A for design of the constructs), we noted a
much reduced target knockdown (52.7%) as compared to
identical shRNAs expressed from the mouse polymerase III U6
promoter (90.2%, see Figure 1B, top panels). These same
lentiviral shRNA vectors were equally potent in driving EGFP
knockdown in human 293T cells (88.0% and 92.5% target
knockdown for shRNA-miR and U6-driven shRNAs respectively,
see Figure 1B lower panels), suggesting that shRNA-miRs might
be less potent in Jurkat T cells as in 293T cells. We set out to
explore the nature of this discrepancy, and assessed whether the
potency of the polymerase II promoter used to express the
miR30-backbone anti-EGFP shRNAs could impact the shRNA-
directed silencing in Jurkat T cells. To this end, we cloned five
different polymerase II promoters upstream the miR-30 anti-
EGFP shRNA cassette that is located in the 39UTR of the
fluorescent protein mCherry to mark cells that have been infected
with the lentiviral construct. We selected the ubiquitin C (UbiC)
promoter, the phosphoglycerate kinase (PGK) promoter, the
cytomegalovirus (CMV) promoter, a beta-actin promoter with an
upstream CMV IV enhancer (CAGGS), and the elongation
factor 1 alpha promoter (EF1A) since these promoters are among
the most commonly used polymerase II promoters to drive
mRNA expression. We analyzed the potency of these promoters
in driving anti-EGFP shRNA expression by measuring EGFP
protein knockdown in EGFP-expressing cells via flow cytometry
(See Figure 2). shRNAs expressed from these promoters displayed
various potency in target-knockdown in Jurkat cells. The
ubiquitin C (UbiC) promoter, the phosphoglycerate kinase
(PGK) promoter, and the cytomegalovirus (CMV) promoter
were equally potent in driving EGFP-target knockdown (52.2%,
52.9%, and 52.7% respectively), whereas the beta-actin promoter
with an upstream CMV IV enhancer (CAGGS, 70.7%), and the
elongation factor 1 alpha promoter (EF1A, 86.3%) were much
more effective (See Figure 2). These data reveal a significant
impact of the choice of polymerase II promoter used in shRNA-
directed target knockdown in human Jurkat T cells.
shRNA-miRs-directed target knockdown is dependent on
cell type and polymerase II used
RNAi is often performed in cells that are relatively easy to
grow and transfect with commercially available lipids. We asked
whether any of the broadly used cell lines would display differing
RNAi effectiveness using our panel of promoters expressing the
same shRNA. To address this question we chose to monitor three
commonly used adherent cell lines (293T embryonic kidney cells,
HeLa cervical carcinoma cells, and HT29 adenocarcinoma cells)
and three commonly used non-adherent immune cell lines (Jurkat
T cell lymphoblast cells, Raji Burkitt lymphoma B cells, and
THP-1 acute monocytic leukemia cells). Stable EGFP-expressing
cells were generated for all six lines, and infected at a low MOI
with the various viruses. EGFP expression was then monitored at
2, 3, 4, 6, and 8 days post infection by flow cytometry (See
Figure 3). In all cases, the EF1A-anti-EGFP construct was most
efficient in driving EGFP knockdown as compared to the other
four polymerase II-promoters. This observation was most
prominent in the non-adherent immune cell types (Raji, Jurkat,
and THP1 cells, See Figure 3 left panels). In general EGFP-
knockdown was more variable using the different polymerase-II
promoters in immune cells as compared to the adherent lines.
The EF1A, CAGGS and CMV promoters were equally potent in
293T and HeLa cells, whereas the PGK and UbiC promoters
displayed much-reduced EGFP-target knockdown in these lines.
Optimal EGFP-knockdown was observed 6 to 8 days post
infection for all promoters in all lines. In Table 1 we present a
summarizing overview of the RNAi efficiencies of the tested
promoters in the different cell lines.
Although some groups reported that miR-backbone expressed
shRNAs are more potent as polymerase III U6-promoter
Figure 2. shRNA-miR-directed target knockdown is highly
dependent on the polymerase II promoter used. EGFP-expressing
Jurkat T cells were infected at an MOI of ,0.2 with anti-EGFP shRNA-
miRs (left panels) or controls (no shRNA insert, right panels) driven by
various indicated polymerase-II promoter. Cells were allowed to grow
for 8 days and the expression EGFP (to monitor knockdown) and
mCherry (as marker for infected cells) were assessed by flow cytometry.
The indicated percentage of EGFP knockdown is calculated by ((Geo-
mean of uninfected cells minus Geo-mean of infected cells)/Geo-mean
of uninfected cells)*100. The presented data is a representative
experiment of 2 experiments performed in triplicate.
doi:10.1371/journal.pone.0026213.g002
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contrast, the U6 promoter expressed shRNAs were more potent in
directing target knockdown as compared to the most effective
EF1A promoter in all 6 cell lines (See Figure 3 and Figure 4A).
The U6 promoter caused an additional target knockdown of
22.5%, 10.4%, and 30.7% in 293T, HeLas, and HT29 cells as
compared to the EF1A promoter (see Figure 4A). This enhanced
target knockdown was even more pronounced in the immune lines
Raji, Jurkat and THP1 in which an additional 47.7%, 26.5%, and
50.3% of target knockdown was achieved over the EF1A promoter
(Figure 4A). We conclude that shRNA-miRs efficacy is largely
dependent on the polymerase II used to drive expression of the
shRNA, and that this differential target knockdown is dependent
on the cell type used.
Figure 3. Efficacy of shRNA-miRs-guided target knockdown in various cell lines is dependent on the type of polymerase II promoter
used. EGFP-expressing human immune cell types (Raji B cells, Jurkat T cells, and THP-1 monocytic cells) and adherent cell lines (293T, HeLa, and HT29
cells) were infected at an MOI of ,0.2 with anti-EGFP shRNAs expressed from a miR-30 backbone driven by various indicated polymerase-II promoter.
Cells were allowed to grow for the indicated number of days and the expression of EGFP (to monitor knockdown) and mCherry (as marker for
infected cells) was assessed by flow cytometry. The presented percentage of EGFP knockdown is calculated by ((Geo-mean of uninfected cells minus
Geo-mean of infected cells)/Geo-mean of uninfected cells)*100. The presented data is a representative experiment of 2 experiments performed in
triplicate. For all data points, the standard deviation was below 5%.
doi:10.1371/journal.pone.0026213.g003
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backbone-expressed shRNAs
We assessed whether EGFP-target knockdown in the tested cell
lines correlates with the relative polymerase II promoter strength
in those lines. To determine the relative strength of the promoter,
we measured the mCherry transgene fluorescence as a proxy for
promoter activity. However, when shRNAs were present within
the 39UTR of the mCherry transgene, we noted a clear reduced
expression (up to 70.6%) of the mCherry gene cloned immediately
upstream of the shRNA-miR (see Figure 4b). This reduced
expression of the reporter is likely due to competition between
mRNA export and microprocessor processing of the anti-EGFP
shRNA out of the mCherry 39UTR, thereby destabilizing the
mCherry transcript. Since this processing could be impacted by
the number of mRNA copies present in the cell, we thus chose to
correlate the relative mCherry expression with viruses not
expressing the miR-30 cassette to the percentage of target
knockdown in cells expressing the shRNAs.
To this end, we measured the relative strength of the promoters
by assessing the mCherry fluorescence of infected cells 8 days post
infection and plotted this to the percentage of target knockdown at
this same time point (see Figure 5). For all lines, there was a clear
correlation between promoter strength (as determined by mCherry
expression) and EGFP-knockdown by the miR30-backbone anti-
EGFP shRNA, suggesting that the strength of the promoter is a
major determinant for shRNA-miR potency.
‘Mature’ anti-EGFP siRNA expression levels correlate with
target-knockdown
If promoter strength is a critical variable for induction of potent
RNAi, the amount of small RNAs should correlate with the
activity of the promoter. To formally test this we quantitated the
relative expression levels of the fully processed anti-EGFP siRNA
antisense strand in the cells expressing the various promoter
constructs. To this end, we designed TaqMan qPCR primers and
probes specific for the ‘mature’ anti-EGFP siRNA based on the
validated TaqMan approach for mature miRNAs [28]. The qPCR
was specific for the mature anti-EGFP siRNA strand (data not
shown) and efficiently amplified this species in our cell lines
expressing anti-EGFP shRNAs driven by either the U6 promoter
or the various polymerase II promoters. We sorted cells expressing
single copies of the various anti-EGFP expressing shRNAs vectors
by FACS, and assessed the relative expression level of mature anti-
EGFP siRNAs herein and plotted this to the percentage of protein
target knockdown at this same timepoint (see Figure 6). Again, for
all lines, there was a clear correlation between promoter strength
(as determined by mature anti-EGFP siRNA expression) and
EGFP-knockdown by the anti-EGFP shRNA. We conclude that a
more potent polymerase II promoter yields higher quantities of
anti-target siRNAs, resulting in higher protein target knockdown.
Of note, since we quantitated the EGFP target knockdown by
measuring the amount of fluorescent protein in the cells and not
by assessing the EGFP mRNA levels, we cannot account for the
impact of differences in EGFP stability on RNAi in these different
cell types.
Discussion
Since the discovery of RNAi and microRNAs more than a
decade ago, an incredible amount of research has been focused on
the development of systems that usurp miRNA biology as a tool to
downregulate protein expression in mammalian cells [1,2,3].
Recent progress has been made with the development of shRNA-
miRs, in which single or even multiple endogenous miRNA pri-
cursors are expressed from polymerase II promoters and the
mature microRNA sequence is replaced by gene specific duplexes
that guide RNAi [17,18,19,20,21,22,23]. Although these tools
proved very effective in directing target mRNA knockdown and
hence reduced protein expression in many cell types, we observed
that the choice of the polymerase II promoter used to drive
shRNA expression is of critical importance to allow effective
mRNA target knockdown. We observed a clear positive
correlation between promoter strength and protein target
knockdown.
Researchers are often not aware that promoter choice directly
impacts target knockdown efficiency and hence could determine
the success of an experiment. We especially caution researchers
that utilize commercial shRNA-miR expression vectors in immune
cells, since these often make use of CMV promoters to drive
expression of gene-specific shRNA-miRs. Although the CMV
promoter causes very efficient expression in many cancer cell lines
of fibroblast and epithelial origin, this promoter is much less active
in lymphohematopoietic cells such as T, B and monocytic cells as
we and others [29,30] have shown. This often-underappreciated
fact not only impacts transgene expression of protein coding genes
in immune cells, but also negatively impacts the expression levels
of shRNA-miRs thereby lowering the silencing capacity of these
RNAi molecules. Since we show a clear positive correlation
between promoter strength, the level of ‘mature’ siRNA
expression, and protein target knockdown, we recommend using
promoters that have maximum promoter strength in the target cell
of interest to allow optimum protein knockdown using shRNA-
miRs in mammalian cells.
A number of reports have indicated that expression of shRNAs
via polymerase III promoters can cause toxicity in vivo in shRNA-
expressing cells [31,32,33], whereas expression of shRNAs from a
polymerase II promoter attenuates this effect [32,34]. These
shRNA-induced toxicities are believed to be mediated via
saturation of endogenous RNAi export machinery [31,34] or via
off-target silencing of unintended mRNAs through buildup of
antisense RNAs [32]. We have not observed delayed growth of
cells expressing shRNAs from the polymerase III U6 promoter in
our experiments (data not shown), and hence have no evidence of
toxic effects by shRNA expressed via this system. Nevertheless, we
cannot exclude that overexpressing shRNAs through very potent
polymerase II or III promoters could induce toxicity in other in
Table 1. Overview of the efficacy of shRNA-miRs-guided
target knockdown in various human cell lines.
Raji Jurkat THP1 293T HeLa HT29
U6 90.560.3 90.260.2 95.260.1 92.560.1 92.360.2 97.460.1
EF1A 80.062.2 86.360.2 90.560.2 90.260.1 90.760.1 95.860.1
CAGGS 53.460.9 70.761.8 84.760.7 91.860.1 89.964.3 86.860.8
CMV 50.061.6 52.763.7 61.563.0 88.060.4 91.960.2 77.760.3
PGK 44.361.2 52.960.7 71.860.8 71.963.3 65.363.8 80.660.3
UbiC 26.861.0 52.262.4 72.262.4 60.260.4 56.764.9 76.760.7
EGFP-expressing human cell lines (see top row) were infected at an MOI of ,0.2
with anti-EGFP shRNAs expressed from a miR-30 backbone driven by various
indicated polymerase-II promoters (left column). Cells were allowed to grow for
8 days and the percentage of EGFP target knockdown was assessed by flow
cytometry (see Figure 3 for details). The presented data is a representative
experiment of 2 experiments performed in triplicate.
doi:10.1371/journal.pone.0026213.t001
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potential toxic effect may or may not be a concern in experiments
with shRNAs in cell lines, caution is necessary when studying the
in vivo roles of genes or when designing shRNAs for therapeutic
purposes.
We and others [35] have noted that cloning of shRNA-miRs
downstream of a reporter gene causes reduced protein expression
of the upstream gene. This observation is likely caused by
processing of the anti-EGFP shRNA out of the reporters 39UTR
by the microprocessor, thereby destabilizing the mRNA transcript.
This observation proved especially problematic in cells where the
polymerase II promoter drives naturally low expression of the
reporter gene, since shRNA clipping reduced reporter expression
to (almost) undetectable levels (data not shown). To allow optimal
detection of reporter expression of shRNA-miR containing
expression vectors, the reporter gene(s) should be expressed from
a different polymerase II promoter.
Although U6 driven shRNA expression is optimal for efficient
target knockdown in a broad range of cell lines, shRNA-miRs
expressed from polymerase II promoters allow for cell or tissue
specific silencing of target mRNAs. This feature may be
particularly useful to study the function of genes in a specific cell
type in stable knockdown mice. However, in order to obtain good
target knockdown, tissue specific expression of shRNA-miRs alone
is not adequate, as the promoter that drives expression of the




Cell lines were obtained from the American Type Culture
Collection (Manassas, VA) and cultured using standard tech-
niques. Human cell lines that were used in this study are: 293T
embryonic kidney cells, HeLa cervical carcinoma cells, HT29
adenocarcinoma cells, Jurkat T cell lymphoblast cells, Raji Burkitt
lymphoma B cells, and THP-1 acute monocytic leukemia cells.
The pSicoR-EGFP lentiviral vector [8] was used as backbone
vector to express EGFP and a puromycin resistence gene under
control of the EF1A promoter. These proteins were fused by the
viral T2A sequence [26] to allow expression of two separate
proteins from the same mRNA transcript.
An anti-EGFP shRNA sequence (59-GCAAGCTGACCCT-
GAAGTTCTTCAAGAGAGAACTTCAGGGTCAGCTTGCT-
TTTTT-39) was cloned downstream of the polymerase III U6
promoterinpSicoR [8];thisvector alsoencodes mCherryunderthe
control of the EF1A promoter. The loop of the shRNA is indicated
in bold and the polymerase III terminator is underlined. A similar
anti-EGFP shRNA sequence with the miR30 loop (bold) was cloned
between miR30 pricursor arms (underlined and italic) downstream
of mCherry in the same vector (AAGAAGGTATATTGCTGTTGA-
CAGTGAGCGTCAAGCTGACCCTGAAGTTCATTAGTGAA-
GCCACAGATGTAATGAACTTCAGGGTCAGCTTGCTGC-
CTACTGCCTCGGACTTCAAGGGG), the U6 promoter unit was
removed.
Figure 4. anti-EGFP shRNAs expressed from a mouse U6
promoter is more potent as compared to anti-EGFP shRNA-
miRs expressed from an EF1A-promoter. A) EGFP-expressing
human immune cell types (Raji B, Jurkat T, and THP-1 monocytic cells)
and adherent cell lines (293T, HeLa, and HT29 cells) were infected at an
MOI of ,0.2 with anti-EGFP shRNAs expressed from a mouse U6
promoter (blue histograms) or with anti-EGFP shRNA-miRs expressed
from the human EF1A promoter (red histograms). Eight days post
infection, infected cells were monitored for EGFP expression by flow
cytometry. The presented percentage of EGFP knockdown of the U6-
driven shRNAs relative to the EF1A-driven shRNAs is calculated by
((Geo-mean of EF1A infected cells minus Geo-mean of U6 infected
cells)/Geo-mean of EF1A infected cells)*100. B) mCherry expression is
reduced upon cloning of an shRNA-containing miR-30 cassette in the
39UTR of the fluorescent protein. Two examples are shown where either
the CAGGS or EF1A promoter drives expression of mCherry with/
without a functional miR cassette in it’s 39UTR. The percentage of
reduced relative mCherry expression caused by the miR-cassette
containing UTR is indicated. The presented data are representative
experiments of 2 experiments performed in triplicate.
doi:10.1371/journal.pone.0026213.g004
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PGK, UbiC, CAGGS, EF1A) were cloned upstream of mCherry
in the miR30-anti-EGFP vectors and control (mCherry alone)
vectors. The CMV and PGK promoters were amplified from
pSicoR and pSicoR PGK respectively [8], the UbiC promoter was
obtained from pDSL_hpUGIH (ATCC), the CAGGS promoter
was amplified from pCAGGS (BCCM), and the EF1A promoter
was amplified from the pEF6 vector (Invitrogen). All constructs
were sequence verified by conventional DNA sequencing
technologies.
Virus Generation and generation of stable transfectants
Lentiviruses were generated essentially as described [27].
Briefly, 4 mg of lentiviral vector and 1.33 mg of each packaging
vector (pMD2G-VSVg, pRSV-REV, and pMDL/RRE) were
cotransfected in 293T cells by using the FuGENE 6 reagent
(Roche Diagnostics). Supernatants were collected 48 h after
transfection, filtered through a 0.25-mm filter, and used directly
to infect target cells. For infections of suspension cells (Raji, Jurkat,
THP-1), ,5610
5 cells were spinfected for 1.5 hours at 1000 g at
33uC in 24 well-plates in the presence or ,1610
5 lentiviral
particles in culture medium supplemented with 8 mg/ml polybrene
(Sigma–Aldrich, St. Louis, MO). Adherent cells were infected with
similar conditions, although these were not subjected to spinfec-
tion. To generate EGFP-expressing cellines, 293T, HeLa, HT29,
Raji, Jurkat, and THP-1 cells were infected with pSicoR-EGFP-
T2A-Puromycin virus at low MOI (,0.1) to ensure single viral
integrations. Individual EGFP-positive cells were single-cell sorted
by using a Moflow cell sorter (Dakocytomation, Ft. Collins, CO) in
96 well plates, allowed to recover in the presence of puromycin
Figure 5. Promoter strength determines potency of shRNA-miRs. EGFP-expressing human immune cell types (Raji B, Jurkat T, and THP-1
monocytic cells) and adherent cell lines (293T, HeLa, and HT29 cells) were infected at an MOI of ,0.2 with anti-EGFP shRNAs (left panels) expressed
from a miR-30 backbone driven by various polymerase-II promoter. Cells were allowed to grow for 8 days and the expression of EGFP (to monitor
knockdown) was assessed by flow cytometry. Relative promoter strength of the polymerase II promoters (mCherry Geo Mean) was measured from
control vectors that lacked the miR30-backbone, since processing of shRNAs out of the miR30 backbone destabilized the transcript. Relative
promoter strength is plotted against% EGFP knockdown in the indicated cellines. Trendlines and R
2 values of fitted curves are indicated.
doi:10.1371/journal.pone.0026213.g005
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weeks later. All clonal cellines uniformly expressed high levels of
EGFP.
Monitoring EGFP knockdown by shRNAs expressed from
miR-30 backbone vectors
Stable EGFP-expressing cell lines were infected at low MOI
(,0.2) with lentivirus expressing anti-EGFP shRNAs expressed
from various polymerase II promoters described above or from the
mouse polymerase pol-III U6 promoter as control. As additional
controls, cells were infected with the same viruses lacking a miR-
30-anti-EGFP unit. EGFP knockdown was monitored at various
timepoints post-infection by flow cytometry on the FACSarray
system (Becton Dickinson, CA). Percentage of EGFP knockdown
was calculated by ((Geo-mean of uninfected cells minus Geo-mean
of infected cells)/Geo-mean of uninfected cells)*100. Infected cells
were discriminated from uninfected cells by means of mCherry-
expression encoded on the lentiviral vector.
Quantization of mature anti-EGFP siRNA expression
Cells stably expressing anti-EGFP shRNAs from the various
polymerase II promoters were sorted by using a Moflow cell sorter
(Dakocytomation, Ft. Collins, CO) based on mCherry marker
expression.Thecellswereallowedtorecoverandwere subsequently
subjected to total RNA extraction by using the Trizol reagent
according manufacturers recommendations (Invitrogen, Carlsbad,
CA).Expression ofthematureanti-EGFPstrand wasdeterminedby
real-time PCR essentially as described [28]. In short, 20 ng total
RNA was reverse transcribed by using an EGFP-siRNA-specific
stem-loop RT primer (59-CTCAACTGGTGTCGTGGAGTC-
Figure 6. Relative quantity of anti-EGFP siRNAs correlates with target-knockdown. EGFP-expressing human immune cell types (Raji B,
Jurkat T, and THP-1 monocytic cells) and adherent cell lines (293T, HeLa, and HT29 cells) were infected at an MOI of ,0.2 with anti-EGFP shRNAs (left
panels) expressed from a miR-30 backbone driven by various polymerase-II promoters. Cells were allowed to grow for 8 days and the expression of
EGFP (to monitor knockdown) was assessed by flow cytometry. Total RNA was isolated and relative mature anti-EGFP siRNA expression was
determined by TaqMan analysis. The lowest quantity of mature anti-EGFP within each cell line was set to 1. Relative mature anti-EGFP siRNA
expression is plotted against% EGFP knockdown in the indicated cellines. Trendlines and R
2 values of fitted curves are indicated.
doi:10.1371/journal.pone.0026213.g006
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MyCycler Thermal Cycler System at 16uC, 30 min at 42uC, 5 min
at 85uC and then held at 4uC. Subsequently, Real-time PCR was
performed as described[28] on an Applied Biosystems 7900HT
Sequence Detection System (Applied Biosystems, Foster City, CA)
in a 384-well plate at 95uC for 10 min, followed by 40 cycles of
95uC for 15 s and 58uC for 1 min. All reactions were run in
triplicate. The EGFP forward oligo (59-ACACTCCAGCTGGG-
GAACTTCAGGGTCAG-39)andtheEGFP-siRNA-specificprobe
59-56-FAM-TTCAGTTGAGTGCAAGCT-3IABLFQ-39 were
purchased from IDT DNA Technology (Coralville, IA, USA).
The expression of the processed anti-EGFP siRNA was normalized
to expression of the U6 snoRNA (Applied Biosystems, Foster City,
CA) as determined by miRNA Taqman analysis according the
manufacturer’s instructions.
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